Hearn Cho
Chief Medical Officer · Multiple Myeloma Research Foundation
Credentials: · · · · · ·
History
- 2000–2002
Medical Oncology
Research
Cloning and characterization of inducible nitric oxide synthase from mouse macrophages
Science · 1992 · 1,823 citations
Proceedings of the National Academy of Sciences of the United States of America · 1991 · 746 citations
Calmodulin is a subunit of nitric oxide synthase from macrophages
The Journal of Experimental Medicine · 1992 · First of 7 authors · 575 citations
48 papers
45 papers
45 papers
35 papers
30 papers
- DM
24 papers
22 papers · 3 as a fellow
16 papers
Grants
- 2014–2016
Novel Therapeutic Strategies Targeting Conformational Plasticity of Type I MAGE
National Cancer Institute · R21
Contact PI · $405.7K · Icahn School of Medicine at Mount Sinai
- 2006–2011
Type 1 MAGE Vaccine Immunotherapy for Multiple Myeloma
National Cancer Institute · K01
Contact PI · $776.5K · New York University School of Medicine
Clinical trials
- 2026–2035
Horizon Two: HR NDMM (MMRC-100)
Principal investigator · Recruiting · Phase 2
Multiple Myeloma Research Consortium
- 2024–2030
MMRC Horizon One: RRMM (MMRC-099)
Principal investigator · Active not recruiting · Phase 2
Multiple Myeloma Research Consortium
- 2020–2023
MMRF CureCloud Research Initiative
Principal investigator · Terminated
Multiple Myeloma Research Foundation
- 2020–2024
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Principal investigator · Terminated · Phase 1, Phase 2
Multiple Myeloma Research Consortium